Brought to you by 
Ascletis raises $100mm in Series B round
17 Jan 2017
Executive Summary
Ascletis Inc. raised $100mm in its Series B financing led by C-Bridge Capital, which was joined other Series A backers Goldman Sachs and Tasly Pharmaceutical and new investors including QianHai Equity Investment FOF, FOCUS Media Jiangnanchun Foundation, and WTT Investment. The company plans to use the funds for ongoing pipeline development and sales force expansion. Ascletis has been focusing on therapies for hepatitis C but now plans to move into hepatitis B and other liver diseases.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ascletis raises $100mm in Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice